2.30Open2.30Pre Close0 Volume1 Open Interest80.00Strike Price0.00Turnover450.99%IV69.40%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0251Delta0.0003Gamma110.40Leverage Ratio-0.5482Theta-0.0021Rho-2.77Eff Leverage0.0239Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet